Kathrin Nachtkamp (K Nachtkamp)

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Venues

Leukemia

Cancers

Blood advances

This page only lists publications with an associated author ORCID identifier.

Publications

Felicitas Schulz, Paul S Jäger, Johanna Tischer, Alessia Fraccaroli, Gesine Bug, Andreas Hausmann, Ben-Niklas Baermann, Patrick Tressin, Alexander Hoelscher, Annika Kasprzak, Kathrin Nachtkamp, Johannes Schetelig, Inken Hilgendorf, Ulrich Germing, Sascha Dietrich, Guido Kobbe
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers 16 (3) (2024)
Annika Kasprzak, Julia Andresen, Kathrin Nachtkamp, Andrea Kündgen, Felicitas Schulz, Corinna Strupp, Guido Kobbe, Colin R Mackenzie, Jörg Timm, Sascha Dietrich, Norbert Gattermann, Ulrich Germing
Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry. Cancers 16 (4) (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia 38 (2) (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia 38 (2) (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia 38 (2) (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia 38 (2) (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia 38 (2) (2024)
Felicitas Schulz, Paul S Jäger, Johanna Tischer, Alessia Fraccaroli, Gesine Bug, Andreas Hausmann, Ben-Niklas Baermann, Patrick Tressin, Alexander Hoelscher, Annika Kasprzak, Kathrin Nachtkamp, Johannes Schetelig, Inken Hilgendorf, Ulrich Germing, Sascha Dietrich, Guido Kobbe
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers 16 (3) (2024)
Kathrin Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, Christina Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul, Sabine Blum, W K Hofmann, M Pfeilstöcker, Peter Valent, M Lübbert, Maximilian Seidl, M Rudelius, R Stauder, O Krieger, K S Götze, J Bobak, A Kündgen, F Schulz, Sascha Dietrich, G Kobbe, N Gattermann, U Germing
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia 38 (2) (2024)
Annika Kasprzak, Julia Andresen, Kathrin Nachtkamp, Andrea Kündgen, Felicitas Schulz, Corinna Strupp, Guido Kobbe, Colin R Mackenzie, Jörg Timm, Sascha Dietrich, Norbert Gattermann, Ulrich Germing
Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry. Cancers 16 (4) (2024)
Michaela Kotrová, Johannes Koopmann, Heiko Trautmann, Nael Alakel, Joachim Beck, Kathrin Nachtkamp, Björn Steffen, Simon Raffel, Andreas Viardot, Klaus Wethmar, Nikos Darzentas, Claudia D Baldus, Nicola Gökbuget, Monika Brüggemann
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood advances 6 (10) (2022)
Amelie Boquoi, Veronika Rings, Annemarie Mohring, Ingrida Savickaite, Romans Zukovs, Judith Strapatsas, Kathrin Nachtkamp, Guido Kobbe, Ulrich Germing, Roland Fenk
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations. Cancers 14 (9) (2022)

Kathrin Nachtkamp.css-eqlu8i{font-size:small;padding-left:4px;} (K Nachtkamp)

Publication Activity (10 Years)

Top Topics

Top Venues

Kathrin Nachtkamp (K Nachtkamp)